Informations générales (source: ClinicalTrials.gov)
National Observatory of the Care of Young Sick Children in Community or Not, Indications and Cost-effectiveness of PCR-Sars-CoV-2 - VIGIL Study (VIGIL)
Observational [Patient Registry]
Centre Hospitalier Intercommunal Creteil (Voir sur ClinicalTrials)
juin 2020
mai 2024
29 juin 2024
The VIGIL study was set up at the beginning of the pandemic, in the spring of 2020, at a
time when diagnostic testing for SARS-CoV-2 had to be performed according to specific
clinical criteria (even if no clinical picture suggestive of COVID had been clearly
identified). The management of sick young children (with respiratory tract infection that
could be attributed to COVID) by pediatricians (infectious diseases specialists,
emergency physicians, general practitioners, and outpatients) was facilitated by an
algorithm whose objective was to help define the indications for SARS-CoV-2 PCR and
subsequently for antigenic testing. The current technique of deep nasopharyngeal swabbing
(for PCR or antigenic testing) is delicate and difficult in children, and is therefore a
serious handicap for community-based screening, especially since infectious episodes are
frequent in children. Since then, nasal self-tests that can be easily used in children
have been commercialized and have facilitated screening.
Because of the similarity between the clinical signs of respiratory tract infections in
children, it is often impossible to distinguish between different viral respiratory
infections and epidemics may overlap in time. However, the identification of the pathogen
is the key to improve management of these infectious diseases. The VIGIL study is
therefore continuing, still facilitated by the existence of an active pediatric network
existing for 20 years. ACTIV AFPA and GPIP have created networks of hospital and
ambulatory pediatricians who actively participate in various observatories
https://www.jpeds.com/article/S0022-3476(17)31606-2/fulltext To date, these observatories
have resulted in the publication of more than 80 articles in international journals
(https://www.activ-france.com/fr/publications).
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHI DE CRETEIL | Isabelle HAU-RAINSARD | 29/03/2024 01:28:56 | Contacter | ||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| ACTIV network - Créteil - France | Corinne LEVY, MD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| PARI network - Créteil - France | Corinne Levy, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Children under 15 years of age
- Prescription of a PCR-Sars-CoV-2
- VIGIL information note given to parents
- Children under 15 years of age
- Prescription of a PCR-Sars-CoV-2
- VIGIL information note given to parents
- Refusal to participate by the patient, family member or legal representative
(depending on the situation)